FunPep Company Limited

Tokyo Stock Exchange 4881.T

FunPep Company Limited Gross Profit for the year ending December 31, 2023: USD -4.82 M

FunPep Company Limited Gross Profit is USD -4.82 M for the year ending December 31, 2023, a 30.61% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • FunPep Company Limited Gross Profit for the year ending December 31, 2022 was USD -6.95 M, a -49.33% change year over year.
  • FunPep Company Limited Gross Profit for the year ending December 31, 2021 was USD -4.65 M, a -32.81% change year over year.
  • FunPep Company Limited Gross Profit for the year ending December 31, 2020 was USD -3.50 M, a -232.11% change year over year.
  • FunPep Company Limited Gross Profit for the year ending December 31, 2019 was USD 2.65 M.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
Tokyo Stock Exchange: 4881.T

FunPep Company Limited

CEO Mr. Toshimi Miyoshi Ph.D., Pharm.D.
IPO Date Dec. 25, 2020
Location Japan
Headquarters No.7 Mizuho Building
Employees 15
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email